 During Phase 1b portion, there will be a dose-escalation of AV-299 formerly SCH 900105 in combination with the recommended dose of gefitinib in subjects with NSCLC or advanced solid tumor. The objective is to determine the safety, tolerability, dose limiting toxicity DLT and recommended Phase 2 dose RP2D in combination with gefitinib for the Phase 2 portion. 